From Krebs to clinic: Glutamine metabolism to cancer therapy

Nature Reviews Cancer

Volumn 16, Issue 10, 2016, Pages 619-634

  Altman, Brian J ^a,b   Stine, Zachary E ^a,b   Dang, Chi V ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; ADENOSINE TRIPHOSPHATE; AGENTS AFFECTING METABOLISM; ANTINEOPLASTIC AGENT; GLUTAMINASE; GLUTAMINE; GLUTAMINE METABOLIC INHIBITOR; GLUTATHIONE; MAMMALIAN TARGET OF RAPAMYCIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; GLUTARIC ACID; GLUTARIC ACID DERIVATIVE;

AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; AUTOPHAGY; CARBOXYLATION; CARCINOGENESIS; ENERGY; FATTY ACID SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC INHIBITION; MOLECULARLY TARGETED THERAPY; MULTIMODAL IMAGING; NUCLEOTIDE METABOLISM; ONCOGENE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STRESS; CITRIC ACID CYCLE; METABOLISM; NEOPLASMS;

ADENOSINE TRIPHOSPHATE; CITRIC ACID CYCLE; GLUTAMINE; GLUTARATES; HUMANS; NEOPLASMS;

EID: 84982993825     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.71     Document Type: Review

References (256)

1. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956).
2. DeBerardinis, R. J., Cheng, T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313-324 (2010).
3. Hensley, C. T., Wasti, A. T., DeBerardinis, R. J. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 123, 3678-3684 (2013).
4. Lacey, J. M., Wilmore, D. W. Is glutamine a conditionally essential amino acid? Nutr. Rev. 48, 297-309 (1990).
5. Rubin, A. L. Suppression of transformation by and growth adaptation to low concentrations of glutamine in NIH-3T3 cells. Cancer Res. 50, 2832-2839 (1990).
6. Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., Lazebnik, Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 178, 93-105 (2007).
7. Mayers, J. R., Vander Heiden, M. G. Famine versus feast: understanding the metabolism of tumors in vivo. Trends Biochem. Sci. 40, 130-140 (2015).
8. Bergstrom, J., Furst, P., Noree, L. O., Vinnars, E. Intracellular free amino acid concentration in human muscle tissue. J. Appl. Physiol. 36, 693-697 (1974).
9. Krebs, H. A. in Glutamine: Metabolism, Enzymology, and Regulation (eds Mora, J., Palacios, R.) 319-329 (Academic Press, 1980).
10. Stumvoll, M., Perriello, G., Meyer, C., Gerich, J. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int. 55, 778-792 (1999).
11. Felig, P., Wahren, J., Raf, L. Evidence of inter-organ amino-acid transport by blood cells in humans. Proc. Natl Acad. Sci. USA 70, 1775-1779 (1973).
12. Taylor, L., Curthoys, N. P. Glutamine metabolism: role in acid-base balance. Biochem. Mol. Biol. Educ. 32, 291-304 (2004).
13. Krebs, H. A., Henseleit, K. Untersuchungen uber die Harnstoffbildung im Tierkörper. Hoppe-Seylers Z. Physiol. Chemie 210, 33-66 (1932).
14. Windmueller, H. G., Spaeth, A. E. Uptake and metabolism of plasma glutamine by the small intestine. J. Biol. Chem. 249, 5070-5079 (1974).
15. Bhutia, Y. D., Babu, E., Ramachandran, S., Ganapathy, V. Amino acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. Cancer Res. 75, 1782-1788 (2015).
16. Wise, D. R., Thompson, C. B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35, 427-433 (2010).
17. Nicklin, P. et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136, 521-534 (2009)
18. Timmerman, L. A. et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24, 450-465 (2013).
19. Kerr, M. C., Teasdale, R. D. Defining macropinocytosis. Traffic 10, 364-371 (2009).
20. Bar-Sagi, D., Feramisco, J. R. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 233, 1061-1068 (1986).
21. Kamphorst, J. J. et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 75, 544-553 (2015).
22. Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633-637 (2013).
23. Palm, W. et al. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell 162, 259-270 (2015).
24. Overmeyer, J. H., Kaul, A., Johnson, E. E., Maltese, W. A. Active ras triggers death in glioblastoma cells through hyperstimulation of macropinocytosis. Mol. Cancer Res. 6, 965-977 (2008).
25. Strohecker, A. M. et al. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov. 3, 1272-1285 (2013).
26. Lin, T. C. et al. Autophagy: resetting glutamine-dependent metabolism and oxygen consumption. Autophagy 8, 1477-1493 (2012).
27. Pochini, L., Scalise, M., Galluccio, M., Indiveri, C. Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health. Front. Chem. 2, 61 (2014).
28. Curthoys, N. P., Watford, M. Regulation of glutaminase activity and glutamine metabolism. Annu. Rev. Nutr. 15, 133-159 (1995).
29. Krebs, H. A. Metabolism of amino-acids: the synthesis of glutamine from glutamic acid and ammonia, and the enzymic hydrolysis of glutamine in animal tissues. Biochem. J. 29, 1951-1969 (1935).
30. Moreadith, R. W., Lehninger, A. L. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J. Biol. Chem. 259, 6215-6221 (1984).
31. DeBerardinis, R. J. et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104, 19345-19350 (2007).
32. Wang, R. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871-882 (2011).
33. Fan, J. et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol. Syst. Biol. 9, 712 (2013).
34. Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101-105 (2013).
35. Hosios, A. M. et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev. Cell 36, 540-549 (2016).
36. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648-660 (2015).
37. Cassago, A. et al. Mitochondrial localization and structure-based phosphate activation mechanism of glutaminase C with implications for cancer metabolism. Proc. Natl Acad. Sci. USA 109, 1092-1097 (2012).
38. Elgadi, K. M., Meguid, R. A., Qian, M., Souba, W. W., Abcouwer, S. F. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol. Genom. 1, 51-62 (1999).
39. Shapiro, R. A., Farrell, L., Srinivasan, M., Curthoys, N. P. Isolation, characterization, and in vitro expression of a cDNA that encodes the kidney isoenzyme of the mitochondrial glutaminase. J. Biol. Chem. 266, 18792-18796 (1991).
40. Lu, W., Zuo, Y., Feng, Y., Zhang, M. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. Tumour Biol. 35, 10699-10705 (2014).
41. Polletta, L. et al. SIRT5 regulation of ammonia-induced autophagy and mitophagy. Autophagy 11, 253-270 (2015).
42. Hebert, A. S. et al. Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol. Cell 49, 186-199 (2013).
43. Zhao, L., Huang, Y., Zheng, J. STAT1 regulates human glutaminase 1 promoter activity through multiple binding sites in HIV-1 infected macrophages. PLoS ONE 8, e76581 (2013).
44. Masamha, C. P. et al. CFIm25 links alternative polyadenylation to glioblastoma tumour suppression. Nature 510, 412-416 (2014).
45. Redis, R. S. et al. Allele-specific reprogramming of cancer metabolism by the long non-coding RNA CCAT2. Mol. Cell 61, 520-534 (2016).
46. Ince-Dunn, G. et al. Neuronal Elav-like (Hu) proteins regulate RNA splicing and abundance to control glutamate levels and neuronal excitability. Neuron 75, 1067-1080 (2012).
47. Xia, Z. et al. Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3?-UTR landscape across seven tumour types. Nat. Commun. 5, 5274 (2014).
48. Gao, P. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765 (2009).
49. Hansen, W. R., Barsic-Tress, N., Taylor, L., Curthoys, N. P. The 3?-nontranslated region of rat renal glutaminase mRNA contains a pH-responsive stability element. Am. J. Physiol. 271, F126-F131 (1996).
50. Colombo, S. L. et al. Anaphase-promoting complex/cyclosome-Cdh1 coordinates glycolysis and glutaminolysis with transition to S phase in human T lymphocytes. Proc. Natl Acad. Sci. USA 107, 18868-18873 (2010).
51. Colombo, S. L. et al. Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. Proc. Natl Acad. Sci. USA 108, 21069-21074 (2011).
52. van den Heuvel, A. P., Jing, J., Wooster, R. F., Bachman, K. E. Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol. Ther. 13, 1185-1194 (2012).
53. Jacque, N. et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood 126, 1346-1356 (2015).
54. Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890-901 (2014).
55. Suzuki, S. et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl Acad. Sci. USA 107, 7461-7466 (2010).
56. Hu, W. et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl Acad. Sci. USA 107, 7455-7460 (2010).
57. Zhang, J. et al. Epigenetic silencing of glutaminase 2 in human liver and colon cancers. BMC Cancer 13, 601 (2013).
58. Liu, J. et al. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget 5, 2635-2647 (2014).
59. Szeliga, M., Bogacinska-Karas, M., Kuzmicz, K., Rola, R., Albrecht, J. Downregulation of GLS2 in glioblastoma cells is related to DNA hypermethylation but not to the p53 status. Mol. Carcinog. https://dx.doi.org/10.1002/mc.22372 (2015).
60. Zhang, C. et al. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. Elife 5, e10727 (2016).
61. Xiang, L. et al. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. Biochim. Biophys. Acta 1833, 2996-3005 (2013).
62. Velletri, T. et al. GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation. Cell Cycle 12, 3564-3573 (2013).
63. Giacobbe, A. et al. p63 regulates glutaminase 2 expression. Cell Cycle 12, 1395-1405 (2013).
64. Xiao, D. et al. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2. Oncotarget 6, 40655-40666 (2015).
65. Qing, G. et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 22, 631-644 (2012).
66. Treberg, J. R., Brosnan, M. E., Watford, M., Brosnan, J. T. On the reversibility of glutamate dehydrogenase and the source of hyperammonemia in the hyperinsulinism/hyperammonemia syndrome. Adv. Enzyme Regul. 50, 34-43 (2010).
67. Yang, C. et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 69, 7986-7993 (2009).
68. Fahien, L. A., Kmiotek, E. Regulation of glutamate dehydrogenase by palmitoyl-coenzyme A. Arch. Biochem. Biophys. 212, 247-253 (1981).
69. Haigis, M. C. et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 126, 941-954 (2006).
70. Frieden, C. Glutamate dehydrogenase v. the relation of enzyme structure to catalytic function. J. Biol. Chem. 238, 3286-3299 (1963).
71. Li, M., Li, C., Allen, A., Stanley, C. A., Smith, T. J. The structure and allosteric regulation of mammalian glutamate dehydrogenase. Arch. Biochem. Biophys. 519, 69-80 (2012).
72. Sancak, Y. et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320, 1496-1501 (2008).
73. Csibi, A. et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153, 840-854 (2013).
74. Erecinska, M., Nelson, D. Activation of glutamate dehydrogenase by leucine and its nonmetabolizable analogue in rat brain synaptosomes. J. Neurochem. 54, 1335-1343 (1990).
75. Sorbi, D., Boynton, J., Lindor, K. D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am. J. Gastroenterol. 94, 1018-1022 (1999).
76. Wroblewski, F., Ladue, J. S. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc. Soc. Exp. Biol. Med. 91, 569-571 (1956).
77. Vroon, D. H., Israili, Z. in Clinical Methods: The History, Physical, and Laboratory Examinations (eds Walker, H. K., Hall, W. D., Hurst, J. W.) (Butterworths, 1990).
78. Awapara, J., Seale, B. Distribution of transaminases in rat organs. J. Biol. Chem. 194, 497-502 (1952).
79. Snell, K. Enzymes of serine metabolism in normal, developing and neoplastic rat tissues. Adv. Enzyme Regul. 22, 325-400 (1984).
80. Phang, J. M., Liu, W., Hancock, C. N., Fischer, J. W. Proline metabolism and cancer: emerging links to glutamine and collagen. Curr. Opin. Clin. Nutr. Metab. Care 18, 71-77 (2015).
81. Liu, W., Phang, J. M. Proline dehydrogenase (oxidase) in cancer. Biofactors 38, 398-406 (2012).
82. Liu, W. et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc. Natl Acad. Sci. USA 109, 8983-8988 (2012).
83. Alberghina, L., Gaglio, D. Redox control of glutamine utilization in cancer. Cell Death Dis. 5, e1561 (2014).
84. Sullivan, L. B. et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell 162, 552-563 (2015).
85. Birsoy, K. et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162, 540-551 (2015).
86. Patel, D. et al. Aspartate rescues s-phase arrest caused by suppression of glutamine utilization in KRas-driven cancer cells. J. Biol. Chem. 291, 9322-9329 (2016).
87. Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting ?-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225-234 (2010).
88. Fan, J., Kamphorst, J. J., Rabinowitz, J. D., Shlomi, T. Fatty acid labeling from glutamine in hypoxia can be explained by isotope exchange without net reductive isocitrate dehydrogenase (IDH) flux. J. Biol. Chem. 288, 31363-31369 (2013).
89. Gameiro, P. A. et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 17, 372-385 (2013).
90. Wise, D. R. et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc. Natl Acad. Sci. USA 108, 19611-19616 (2011).
91. Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380-384 (2012).
92. Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385-388 (2012).
93. Dasgupta, S. et al. Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. J. Clin. Invest. 125, 1174-1188 (2015).
94. Sun, R. C., Denko, N. C. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 19, 285-292 (2014).
95. Jiang, L. et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532, 255-258 (2016).
96. Harding, H. P. et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11, 619-633 (2003).
97. Ye, J. et al. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 29, 2082-2096 (2010).
98. Zhang, J. et al. Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol. Cell 56, 205-218 (2014).
99. Bunpo, P. et al. GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase. J. Biol. Chem. 284, 32742-32749 (2009).
100. Broome, J. D. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J. Exp. Med. 118, 99-120 (1963).
101. Oettgen, H. F. et al. Inhibition of leukemias in man by L-asparaginase. Cancer Res. 27, 2619-2631 (1967).
102. Pui, C.-H., Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166-178 (2006).
103. Sodi, V. L. et al. mTOR/MYC axis regulates O-GlcNAc transferase expression and O-GlcNAcylation in breast cancer. Mol. Cancer Res. 13, 923-933 (2015).
104. Shi, Y. et al. Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia 24, 1588-1598 (2010).
105. Lynch, T. P. et al. Critical role of O-linked ?-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J. Biol. Chem. 287, 11070-11081 (2012).
106. Zachara, N. E. et al. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J. Biol. Chem. 279, 30133-30142 (2004).
107. Housley, M. P. et al. O-GlcNAc regulates FoxO activation in response to glucose. J. Biol. Chem. 283, 16283-16292 (2008).
108. Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA 107, 8788-8793 (2010).
109. Hamanaka, R. B., Chandel, N. S. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem. Sci. 35, 505-513 (2010).
110. Welbourne, T. C. Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. Can. J. Biochem. 57, 233-237 (1979).
111. Godwin, A. K. et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl Acad. Sci. USA 89, 3070-3074 (1992).
112. Rubio, I. et al. Oral glutamine reduces radiation morbidity in breast conservation surgery. JPEN J. Parenter. Enteral Nutr. 37, 623-630 (2013).
113. Cao, Y., Kennedy, R., Klimberg, V. S. Glutamine protects against doxorubicin-induced cardiotoxicity. J. Surg. Res. 85, 178-182 (1999).
114. Botman, D., Tigchelaar, W., Van Noorden, C. J. Determination of glutamate dehydrogenase activity and its kinetics in mouse tissues using metabolic mapping (quantitative enzyme histochemistry). J. Histochem. Cytochem. 62, 802-812 (2014).
115. Laplante, M., Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
116. Jeong, S. M. et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 23, 450-463 (2013).
117. Coloff, J. L. et al. Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metab. 23, 867-880 (2016).
118. Lane, A. N., Fan, T. W. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 43, 2466-2485 (2015).
119. Gaglio, D., Soldati, C., Vanoni, M., Alberghina, L., Chiaradonna, F. Glutamine deprivation induces abortive S-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS ONE 4, e4715 (2009).
120. Sellers, K. et al. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J. Clin. Invest. 125, 687-698 (2015).
121. Ben-Sahra, I., Howell, J. J., Asara, J. M., Manning, B. D. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339, 1323-1328 (2013).
122. Robitaille, A. M. et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-1323 (2013).
123. Mathew, R. et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 137, 1062-1075 (2009).
124. Takamura, A. et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 25, 795-800 (2011).
125. Altman, B. J. et al. Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. Oncogene 30, 1855-1867 (2011).
126. Guo, J. Y. et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 25, 460-470 (2011).
127. Yorimitsu, T., Nair, U., Yang, Z., Klionsky, D. J. Endoplasmic reticulum stress triggers autophagy. J. Biol. Chem. 281, 30299-30304 (2006).
128. Jewell, J. L. et al. Metabolism. Differential regulation of mTORC1 by leucine and glutamine. Science 347, 194-198 (2015).
129. Jung, J., Genau, H. M., Behrends, C. Amino acid-dependent mTORC1 regulation by the lysosomal membrane protein SLC38A9. Mol. Cell. Biol. 35, 2479-2494 (2015).
130. Kim, S. G. et al. Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex. Mol. Cell 49, 172-185 (2013).
131. Palmieri, M. et al. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet. 20, 3852-3866 (2011).
132. Rebsamen, M. et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 519, 477-481 (2015).
133. Wang, S. et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 347, 188-194 (2015).
134. Settembre, C. et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 31, 1095-1108 (2012).
135. Dunlop, E. A., Tee, A. R. mTOR and autophagy: a dynamic relationship governed by nutrients and energy. Semin. Cell Dev. Biol. 36, 121-129 (2014).
136. Dewaele, M., Maes, H., Agostinis, P. ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy 6, 838-854 (2010).
137. Cheong, H., Lindsten, T., Wu, J., Lu, C., Thompson, C. B. Ammonia-induced autophagy is independent of ULK1/ULK2 kinases. Proc. Natl Acad. Sci. USA 108, 11121-11126 (2011).
138. Eng, C. H., Yu, K., Lucas, J., White, E., Abraham, R. T. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci. Signal. 3, ra31 (2010).
139. Locasale, J. W. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat. Rev. Cancer 13, 572-583 (2013).
140. Ye, J. et al. Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. 4, 1406-1417 (2014).
141. Tessem, M. B. et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn. Reson. Med. 60, 510-516 (2008).
142. Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350 (2011).
143. Korangath, P. et al. Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin. Cancer Res. 21, 3263-3273 (2015).
144. Wang, R. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871-882 (2011).
145. Wise, D. R. et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl Acad. Sci. USA 105, 18782-18787 (2008).
146. Wullschleger, S., Loewith, R., Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471-484 (2006).
147. Huang, W. et al. A proposed role for glutamine in cancer cell growth through acid resistance. Cell Res. 23, 724-727 (2013).
148. Jin, L. et al. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell 27, 257-270 (2015).
149. Zaganas, I. et al. The effect of pH and ADP on ammonia affinity for human glutamate dehydrogenases. Metab. Brain Dis. 28, 127-131 (2013).
150. Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013).
151. Le, A. et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 15, 110-121 (2012).
152. Terunuma, A. et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J. Clin. Invest. 124, 398-412 (2014).
153. Thai, M. et al. MYC-induced reprogramming of glutamine catabolism supports optimal virus replication. Nat. Commun. 6, 8873 (2015).
154. Sanchez, E. L., Carroll, P. A., Thalhofer, A. B., Lagunoff, M. Latent KSHV infected endothelial cells are glutamine addicted and require glutaminolysis for survival. PLoS Pathog. 11, e1005052 (2015).
155. Csibi, A. et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr. Biol. 24, 2274-2280 (2014).
156. Chen, Z., Wang, Y., Warden, C., Chen, S. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells. J. Steroid Biochem. Mol. Biol. 149, 118-127 (2015).
157. Gaglio, D. et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 7, 523 (2011).
158. Brunelli, L., Caiola, E., Marabese, M., Broggini, M., Pastorelli, R. Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget 5, 4722-4731 (2014).
159. Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399-408 (2012).
160. Kim, J. W., Tchernyshyov, I., Semenza, G. L., Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177-185 (2006).
161. Keith, B., Johnson, R. S., Simon, M. C. HIF1? and HIF2?: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9-22 (2012).
162. Drogat, B. et al. Acute L-glutamine deprivation compromises VEGF-a upregulation in A549/8 human carcinoma cells. J. Cell. Physiol. 212, 463-472 (2007).
163. Kwon, S. J., Lee, Y. J. Effect of low glutamine/glucose on hypoxia-induced elevation of hypoxia-inducible factor-1alpha in human pancreatic cancer MiaPaCa-2 and human prostatic cancer DU-145 cells. Clin. Cancer Res. 11, 4694-4700 (2005).
164. Zhdanov, A. V., Waters, A. H., Golubeva, A. V., Papkovsky, D. B. Differential contribution of key metabolic substrates and cellular oxygen in HIF signalling. Exp. Cell Res. 330, 13-28 (2015).
165. Kelloff, G. J. et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res. 11, 2785-2808 (2005).
166. Ploessl, K., Wang, L., Lieberman, B. P., Qu, W., Kung, H. F. Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents. J. Nucl. Med. 53, 1616-1624 (2012).
167. Lieberman, B. P. et al. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J. Nucl. Med. 52, 1947-1955 (2011).
168. Venneti, S. et al. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci. Transl Med. 7, 274ra17 (2015).
169. Choi, C. et al. A comparative study of short-and long-TE (1)H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. NMR Biomed. 26, 1242-1250 (2013).
170. Marin-Valencia, I. et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 15, 827-837 (2012).
171. Tardito, S. et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat. Cell Biol. 17, 1556-1568 (2015).
172. Robinson, M. M. et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylaceta mido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 406, 407-414 (2007).
173. Xiang, Y. et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J. Clin. Invest. 125, 2293-2306 (2015).
174. Allen, E. et al. Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep. 15, 1144-1160 (2016).
175. Cheng, T. et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl Acad. Sci. USA 108, 8674-8679 (2011).
176. Kung, H. N., Marks, J. R., Chi, J. T. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet. 7, e1002229 (2011).
177. Yuneva, M. O. et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15, 157-170 (2012).
178. Bott, A. J. et al. Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metab. 22, 1068-1077 (2015).
179. Chakrabarti, G. et al. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ss-lapachone. Cancer Metab. 3, 12 (2015).
180. Chen, L., Cui, H. Targeting glutamine induces apoptosis: a cancer therapy approach. Int. J. Mol. Sci. 16, 22830-22855 (2015).
181. Yang, L. et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol. Syst. Biol. 10, 728 (2014).
182. Wang, Q. et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J. Pathol. 236, 278-289 (2015).
183. Lee, S. Y. et al. Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch. Oncotarget 7, 7925-7939 (2016).
184. Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229-1241 (2015).
185. Gerriets, V. A. et al. Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J. Clin. Invest. 125, 194-207 (2015).
186. Klysz, D. et al. Glutamine-dependent ?-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci. Signal. 8, ra97 (2015).
187. Kamphorst, J. J. et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl Acad. Sci. USA 110, 8882-8887 (2013).
188. Mashimo, T. et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159, 1603-1614 (2014).
189. Comerford, S. A. et al. Acetate dependence of tumors. Cell 159, 1591-1602 (2014).
190. Davidson, S. M. et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 23, 517-528 (2016).
191. Hensley, C. T. et al. Metabolic heterogeneity in human lung tumors. Cell 164, 681-694 (2016).
192. Qing, G. et al. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1?. Cancer Res. 70, 10351-10361 (2010).
193. Shroff, E. H. et al. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc. Natl Acad. Sci. USA 112, 6539-6544 (2015).
194. Budczies, J. et al. Glutamate enrichment as new diagnostic opportunity in breast cancer. Int. J. Cancer 136, 1619-1628 (2015).
195. Perez-Escuredo, J. et al. Lactate promotes glutamine uptake and metabolism in oxidative cancer cells. Cell Cycle 15, 72-83 (2016).
196. Ko, Y. H. et al. Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. Cancer Biol. Ther. 12, 1085-1097 (2011).
197. Van Slyke, D. D. et al. Glutamine as source material of urinary ammonia. J. Biol. Chem. 150, 481-482 (1943).
198. Eagle, H., Oyama, V. I., Levy, M., Horton, C. L., Fleischman, R. The growth response of mammalian cells in tissue culture to L-glutamine and L-glutamic acid. J. Biol. Chem. 218, 607-616 (1956).
199. Klingman, J. D., Handler, P. Partial purification and properties of renal glutaminase. J. Biol. Chem. 232, 369-380 (1958).
200. Eagle, H. Nutrition needs of mammalian cells in tissue culture. Science 122, 501-514 (1955).
201. Kovacevic, Z., Morris, H. P. The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res. 32, 326-333 (1972).
202. Lavietes, B. B., Regan, D. H., Demopoulos, H. B. Glutamate oxidation of 6C3HED lymphoma: effects of L-asparaginase on sensitive and resistant lines. Proc. Natl Acad. Sci. USA 71, 3993-3997 (1974).
203. Reitzer, L. J., Wice, B. M., Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254, 2669-2676 (1979).
204. Ardawi, M. S., Newsholme, E. A. Glutamine metabolism in lymphocytes of the rat. Biochem. J. 212, 835-842 (1983).
205. Newsholme, E. A., Crabtree, B., Ardawi, M. S. The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci. Rep. 5, 393-400 (1985).
206. Flier, J. S., Mueckler, M. M., Usher, P., Lodish, H. F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235, 1492-1495 (1987).
207. Rathmell, J. C. et al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell. Biol. 23, 7315-7328 (2003).
208. Shim, H. et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl Acad. Sci. USA 94, 6658-6663 (1997).
209. Lobo, C. et al. Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem. J. 348, 257-261 (2000).
210. Wellen, K. E. et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev. 24, 2784-2799 (2010).
211. Yelamanchi, S. D. et al. A pathway map of glutamate metabolism. J. Cell Commun. Signal. 10, 69-75 (2016).
212. Ishimoto, T. et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19, 387-400 (2011).
213. Yang, M., Vousden, K. H. Serine and one carbon metabolism in cancer. Nat. Rev. Cancer in the press (2016).
214. Wek, R. C., Ramirez, M., Jackson, B. M., Hinnebusch, A. G. Identification of positive-acting domains in GCN2 protein kinase required for translational activation of GCN4 expression. Mol. Cell. Biol. 10, 2820-2831 (1990).
215. Sood, R., Porter, A. C., Olsen, D. A., Cavener, D. R., Wek, R. C. A mammalian homologue of GCN2 protein kinase important for translational control by phosphorylation of eukaryotic initiation factor-2?. Genetics 154, 787-801 (2000).
216. Chantranupong, L. et al. The CASTOR proteins are arginine sensors for the mTORC1 pathway. Cell 165, 153-164 (2016).
217. Ye, J. et al. GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2. Genes Dev. 29, 2331-2336 (2015).
218. Wolfson, R. L. et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science 351, 43-48 (2016).
219. Duran, R. V. et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol. Cell 47, 349-358 (2012).
220. Qie, S., Chu, C., Li, W., Wang, C., Sang, N. ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J. Cell Biochem. 115, 498-509 (2014).
221. Zhan, H., Ciano, K., Dong, K., Zucker, S. Targeting glutamine metabolism in myeloproliferative neoplasms. Blood Cells Mol. Dis. 55, 241-247 (2015).
222. Mitsuishi, Y. et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22, 66-79 (2012).
223. Ma, L. et al. Control of nutrient stress-induced metabolic reprogramming by PKC? in tumorigenesis. Cell 152, 599-611 (2013).
224. Garcia-Cao, I. et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149, 49-62 (2012).
225. Reynolds, M. R. et al. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene 33, 556-566 (2014).
226. Griffiths, M., Keast, D., Patrick, G., Crawford, M., Palmer, T. N. The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro. Int. J. Biochem. 25, 1749-1755 (1993).
227. Earhart, R. H., Koeller, J. M., Davis, H. L. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses. Cancer Treat. Rep. 66, 1215-1217 (1982).
228. Parmentier, J. H. et al. Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. Leuk. Res. 39, 757-762 (2015).
229. Willems, L. et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 122, 3521-3532 (2013).
230. Chan, W. K. et al. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. Blood 123, 3596-3606 (2014).
231. Reinert, R. B. et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J. Biol. Chem. 281, 31222-31233 (2006).
232. Ollenschlager, G. et al. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur. J. Clin. Invest. 18, 512-516 (1988).
233. Wang, J. B. et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207-219 (2010).
234. DeLaBarre, B. et al. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry 50, 10764-10770 (2011).
235. Ferreira, A. P. et al. Active glutaminase C self-assembles into a supratetrameric oligomer that can be disrupted by an allosteric inhibitor. J. Biol. Chem. 288, 28009-28020 (2013).
236. Hartwick, E. W., Curthoys, N. P. BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase. J. Enzyme Inhib Med. Chem. 27, 861-867 (2012).
237. Stalnecker, C. A. et al. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc. Natl Acad. Sci. USA 112, 394-399 (2015).
238. Grewer, C., Grabsch, E. New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+-dependent anion leak. J. Physiol. 557, 747-759 (2004).
239. Wang, Q. et al. Targeting glutamine transport to suppress melanoma cell growth. Int. J. Cancer 135, 1060-1071 (2014).
240. Colas, C. et al. Ligand discovery for the alanine-serine-cysteine transporter (ASCT2, SLC1A5) from homology modeling and virtual screening. PLoS Comput. Biol. 11, e1004477 (2015).
241. Esslinger, C. S., Cybulski, K. A., Rhoderick, J. F. N?-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorg. Med. Chem. 13, 1111-1118 (2005).
242. Li, C. et al. Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase. J. Biol. Chem. 281, 10214-10221 (2006).
243. Li, C. et al. Green tea polyphenols control dysregulated glutamate dehydrogenase in transgenic mice by hijacking the ADP activation site. J. Biol. Chem. 286, 34164-34174 (2011).
244. Guth, P. S. et al. Evaluation of amino-oxyacetic acid as a palliative in tinnitus. Ann. Otol. Rhinol. Laryngol. 99, 74-79 (1990).
245. Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072 (2012).
246. Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3, e02523 (2014).
247. Fendt, S. M. et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 73, 4429-4438 (2013).
248. Lee, Y. M. et al. Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress. Int. J. Oncol. 48, 399-408 (2016).
249. Pusapati, R. V. et al. mTORC1-dependent metabolic reprogramming underlies escape from glycolysis addiction in cancer cells. Cancer Cell 29, 548-562 (2016).
250. Yang, C. et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol. Cell 56, 414-424 (2014).
251. Katt, W. P., Antonyak, M. A., Cerione, R. A. Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention. Mol. Pharm. 12, 46-55 (2015).
252. Tanaka, K. et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J. Clin. Invest. 125, 1591-1602 (2015).
253. Li, J. et al. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells. Proc. Natl Acad. Sci. USA 112, E21-E29 (2015).
254. Hernandez-Davies, J. E. et al. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J. Transl Med. 13, 210 (2015).
255. Herranz, D. et al. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat. Med. 21, 1182-1189 (2015).
256. Xie, C. et al. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer. Oncotarget 7, 610-621 (2016).